New Two-Drug attack on tough lung cancer
NCT ID NCT02503722
Summary
This early-stage study is testing a new combination of two drugs, sapanisertib and osimertinib, for people with advanced non-small cell lung cancer. The cancer must have a specific genetic change (EGFR mutation) and has gotten worse after treatment with a standard targeted drug. The main goals are to find the safest dose and see what side effects occur when these drugs are given together.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut, 06510, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
Yale University
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.